Pierosandro Tagliaferri

Catanzaro, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 192 publications

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

Journal: Cancer treatment and research communications

Published: August 25, 2026

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Journal: British journal of haematology

Published: March 12, 2026

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: March 11, 2026

The role of the molecular tumor board: learnings from the ROME trial.

The role of the molecular tumor board: learnings from the ROME trial.

Journal: NPJ precision oncology

Published: November 18, 2025

CT-based radiomics as a non-invasive virtual biopsy for high PD-L1 expression prediction in non-small cell lung cancer.

CT-based radiomics as a non-invasive virtual biopsy for high PD-L1 expression prediction in non-small cell lung cancer.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: November 01, 2025

Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies.

Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies.

Journal: The journal of liquid biopsy

Published: October 08, 2025

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

Journal: Hematological oncology

Published: September 24, 2025

PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma.

PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma.

Journal: Cancer cell international

Published: September 10, 2025

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

Journal: ESMO open

Published: September 07, 2025

CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy.

CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy.

Journal: Cancers

Published: July 19, 2025

Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC.

Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC.

Journal: Frontiers in immunology

Published: May 25, 2025

Showing 1-12 of 192

Last Updated: 09/26/2026